Health ProductsDear Healthcare Professional Letter

Archived – Product Recall Notice PROGLYCEM Suspension – Schering Canada Inc.

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Schering Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on PROGLYCEM Suspension

June 1, 2004

Subject: URGENT - Product Recall Notice PROGLYCEM® Suspension DIN 00503320 Lot# 2GJAB02, 3GJAB01, 3GJAB02A

Dear Health Care Professional,

Schering Canada Inc, has decided, in consultation with Health Canada, to recall the lots 2GJAB02, 3GJAB01, 3GJAB02A of the product Proglycem Suspension (DIN 00503320) due to elevated diazoxide assay results.

Oral diazoxide is useful in the management of hypoglycemia due to hyperinsulinism. Please take note that an overdose of diazoxide can cause hyperglycemia which may be associated with ketoacidosis as well as sodium and fluid retention. Given the rare conditions under which the drug is used, the fact that the oral suspension would largely be used by pediatric patients who are increasingly vulnerable to complications, the likelihood of comorbid disease and the severity of the possible complications that may occur from a supra-potent lot, Health Canada has assessed this situation to pose a Type I Health Hazard.

Health Canada strongly urges prescribing physicians to immediately contact their patients currently taking this product in order to more closely supervise and adjust dosages, if necessary, based on careful monitoring of blood or urine glucose and/or ketones. Health Canada advises that patients be made aware of the signs and symptoms of the complications that may occur from a supra-potent product and the necessity for increased and adequate blood glucose monitoring.

This product recall is being initiated with all distributors, wholesalers and direct pharmacy accounts that have received those batches. Additionally, we want to inform you as health care professionals involved in the treatment of patients receiving this medication. Please take note that no other lots of this product and no alternative Canadian source of diazoxide suspension are currently available.

An alternate source of diazoxide oral suspension may be obtained through Health Canada's Special Access Programme at (613) 941-2108. Requests can be faxed at (613) 941-3194 and forms are available on Therapeutic Products Directorate website at http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php.

The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of suspected adverse reactions in patients receiving PROGLYCEM® SUSPENSION should be reported to Schering Canada Inc or Health Canada at the following addresses:

Schering Canada Inc.
3535 Trans-Canada Highway
Pointe-Claire, Quebec H9R 1B4
Tel : (800) 463-5442
Fax : (800) 369-3090

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

Schering Canada Inc. is committed to supplying you with high quality products and ensuring the highest level of patient care. Please do not hesitate to contact our Medical Services at (800) 463-5442 if you need any additional information concerning this recall.

Sincerely yours,

original signed by

Patrice Larose, B.Pharm., Ph.D.
Vice President, Regulatory Affairs, Drug Safety and Medical Services

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime